CIPLA vs SMSPHARMA: Stock Comparison

Cipla Ltd vs SMS Pharmaceuticals Limited

Live data: 22 July 2026, 2:35 PM IST • Source: NSE and company filings

Cipla Ltd is the larger company by market capitalisation. Cipla Ltd shows a lower P/E, a higher dividend yield and faster revenue growth, while SMS Pharmaceuticals Limited shows a higher ROE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Cipla Ltd and SMS Pharmaceuticals Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, CIPLA is more favourable on 10 of 13 scored metrics and SMSPHARMA on 3These counts are context-free and are not an overall rating.

Key Differences

Market Cap
CIPLA is the larger company
₹1.14 L Cr vs ₹3,616 Cr
P/E Ratio
CIPLA has a lower P/E
29.83x vs 35.59x
P/B Ratio
CIPLA has a lower P/B
3.36x vs 4.62x
EPS
CIPLA has higher earnings per share
₹48.01 vs ₹11.17
Dividend Yield
CIPLA has a higher dividend yield
0.9% vs 0.1%
Revenue Growth (TTM YoY)
CIPLA has faster revenue growth
-2.1% vs -4.1%
EPS Growth (TTM YoY)
SMSPHARMA has faster EPS growth
49.2% vs -54.6%
Qtr Sales Growth
CIPLA has stronger quarterly sales growth
-2.8% vs -4.13%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricCIPLASMSPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricCIPLASMSPHARMA
Live Price₹1,411.5₹386.45
Day Change-1.47%-0.45%
Volume12.89 L1.24 L
52-Week High₹1,673₹447.8
52-Week Low₹1,165.7₹207.99
Distance from 52W High-15.63%-13.7%

Valuation

MetricCIPLASMSPHARMA
Market Cap₹1.14 L Cr₹3,616 Cr
P/E Ratio29.83x35.59x
P/B Ratio3.36x4.62x
EPS₹48.01₹11.17
Book Value₹426.25₹81.83
Dividend Yield0.9%0.1%

Growth

MetricCIPLASMSPHARMA
Revenue Growth (TTM YoY)-2.1%-4.1%
EPS Growth (TTM YoY)-54.6%49.2%
Qtr Sales Growth-2.8%-4.13%
Qtr Profit Growth-54.6%61%

Profitability & Leverage

MetricCIPLASMSPHARMA
ROE11.6%14.3%
ROCE15.5%13.3%
Net Margin13.96%11.5%
Operating Margin20.9%19.3%
Debt to Equity0.02x0.46x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricCIPLASMSPHARMA
Promoter Holding9.17%68.07%
FII Holding22.56% 1.37 pp0.65% 0.34 pp
DII Holding31.97% 1.25 pp2.83% 0.19 pp
Public Holding16.25% 0.12 pp28.45% 0.15 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Cipla Ltd and SMS Pharmaceuticals Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.